Subcutaneous administration ... in anti-VEGF treatment burden for both indications Bilateral treatment effect with 66.7% reduction in fellow eye IVT injections for wet AMD subjects and 85.8% ...

Subcutaneous immunotherapy (SCIT ... effectiveness of SCIT compared with conventional medication treatment, novel indications and formulations for SCIT are also explored in this review.

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the ... across almost all of Opdivo's lengthy list of indications in nearly a dozen different types ...

Bristol Myers Squibb (BMS) has announced that an injectable version of its cancer immunotherapy Opdivo (nivolumab) has been ...

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection ... provides a new self-injection option across both approved indications in the U.S. that is ...

Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product ...

though local injection site reactions were more common. The FDA approved subcutaneous Opdivo for adult solid tumor indications, enhancing patient treatment experience and healthcare efficiency.

Maintenance of vision and anatomical improvements in study eye and fellow eye of patients previously treated with intravitreal anti-VEGF First-in-class dendrimer nanomedicine that treats both eyes ...